Global Blood Glucose Test Strips Market - Segmented by Device Type, Application and Geography - Growth, Trends and Forecasts (2018 - 2023)

  • ID: 4402777
  • Report
  • Region: Global
  • 110 pages
  • Mordor Intelligence
1 of 4


  • Abbott Laboratories
  • Arkay Inc.
  • Bayer Healthcare Ag
  • F. Hoffmann-La Roche
  • Lifescan
  • MORE
In 2017, the global blood glucose test strips market was estimated at around USD 11,000 million. The market is expected to register a CAGR of about 6.5% during 2018-2023 (the forecast period). North America, followed by Asia-Pacific, accounts for the largest share in the blood glucose test strips market.

Convenience of CGM over Conventional Monitoring

Continuous glucose monitoring (CGM) provides a frequent and real-time feedback about glucose levels and retrospective 24-hrs glucose profiles. Incorporating CGM in the treatment of type 1 diabetes (T1D) has given potential advantages over conventional self-monitoring of blood glucose (SMBG). The real-time use of CGM results can equip people with T1D and parents of youths with T1D, to respond promptly and address glycemic excursions, minimizing, both, hyperglycemia and hypoglycemia. Retrospective use of CGM profiles can reveal recurring glycemic fluctuations that are not apparent with conventional SMBG, permitting regimen adjustments to stabilize glucose control. As CGM systems have become more widespread, the market for blood glucose test strip is likely to experience growth. Moreover, owing to the rising diabetic population and technological advancements, this market is expected to grow and combat diabetes.

High Cost Per Strip

Diabetes treatment requires constant monitoring of glucose levels. If blood glucose levels are not monitored regularly, it can lead to severe complications. Diabetes management process is an expensive service. At large scale, patients use blood glucose test strips. The retail cost of these strips varies from 50 cents per strip to as high as USD 5 per strip. Since, constant monitoring is necessary for diabetic patients, the cost often becomes a problem. Although various countries, like the United Kingdom, provide reimbursements for prescribed test strips, the majority patients have to pay for them from their pockets. The frequency of monitoring glucose levels depends on the type of diabetes and varies from patient to patient. For type 1 diabetes patients, at least four tests are advised per day. If the patient is using insulin injections, the count can go up to seven tests per day. Therefore, if a patient performs 5-6 tests in a day, the average expenditure on test strips would be over USD 180 each month. These expenses add to the already high diabetes management costs and are impeding the market growth.

North America to Dominate the Market Growth

North America accounted for the largest share of 56% of the global market, owing to the availability of healthcare reimbursements and the fastest adoption rate for new medical technologies. Europe is also the leading region in the global blood glucose test strips market. Asia-Pacific is the fastest growing region for blood glucose test strips market and portrays a huge potential for growth in the future, due to the increasing government initiatives to combat diabetes and corporate investments to streamline R&D in diabetes.

Key Developments in the Market
  • January 2018: Ascensia Diabetes Care announced the expansion of its strategic alliance with Insulet Corporation, a leader in tubeless insulin pump technology, by signing a global commercial agreement. This expansion follows the worldwide non-exclusive development agreement that Ascensia announced in June 2017, to connect its CONTOUR®NEXT ONE blood glucose monitoring system (BGMS) with Insulet's next-generation Omnipod System (Omnipod DASH™).

Reasons to Purchase this Report
  • Current and future the blood glucose test strips market outlook in the developed and emerging markets
  • Analyzing various market perspectives, with the help of Porter’s five forces analysis
  • The segment that is expected to dominate the market
  • The regions that are expected to witness fastest growth during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players
  • 3 months analyst support, along with the Market Estimate sheet (in excel)
This report can be customized to meet your requirements. Please contact us for more information.
Note: Product cover images may vary from those shown
2 of 4


  • Abbott Laboratories
  • Arkay Inc.
  • Bayer Healthcare Ag
  • F. Hoffmann-La Roche
  • Lifescan
  • MORE
1. Introduction
1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threats of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry

6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Convenience of CGM Over Conventional Monitoring
6.1.2 Early Detection of Hypo and Hyperglycemic Diabetes
6.1.3 Technological Innovations
6.1.4 Global Rise in Diabetic Population
6.2 Market Restraints
6.2.1 Developed Markets Have Reached Saturation
6.2.2 High Cost per Strip
6.2.3 Difficulty in Product Differentiation
6.3 Opportunities
6.4 Key Challenges

7. Market Segmentation
7.1 By Device Type
7.1.1 Blood Glucose Meter
7.1.2 Blood Glucose Testing Strips
7.1.3 Lancets
7.1.4 Continuous Glucose Monitoring Devices (CGM)
7.1.5 Others
7.2 By Application
7.2.1 Diagnostic Centers/Clinics
7.2.2 Hospitals
7.2.3 Home Setting
7.3 By Geography
7.3.1 North America US Canada Mexico
7.3.2 Europe Germany UK France Italy Spain Rest of Europe (RoE)
7.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
7.3.4 Middle East & Africa GCC South Africa Rest of the Middle East & Africa
7.3.5 South America Brazil Argentina Rest of South America

8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches

9. Key Players
9.1 Lifescan
9.2 Bayer Healthcare Ag
9.3 Abbott Laboratories
9.4 Arkay Inc.
9.5 Roche Diagnostic
9.6 Acon Laboratories
9.7 Apex Biotechnology Corporation
9.8 Ascensia Diabetes Care Holdings
9.9 HMD Biomedical
9.10 B. Braun Melsungen AG
9.11 Others

10. Future of the Market
Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • F. Hoffmann-La Roche
  • Lifescan
  • Bayer Healthcare Ag
  • Abbott Laboratories
  • Arkay Inc.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown